Marco Aguggia

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli et al. · The Journal of Headache and Pain · 2021 · 150 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients

Piero Barbanti, Gabriella Egeo, Cinzia Aurilia et al. · The Journal of Headache and Pain · 2022 · 117 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

Roberto Cantello, Marco Aguggia, M Gilli et al. · Journal of Neurology Neurosurgery & Psychiatry · 1989 · 94 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Maintenance of response and predictive factors of 1‐year <scp>GalcanezumAb</scp> treatment in real‐life migraine patients in <scp>Italy</scp>: The multicenter prospective cohort <scp>GARLIT</scp> study

Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano et al. · European Journal of Neurology · 2022 · 71 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +17

Efficacy of Ginkgolide B in the prophylaxis of migraine with aura

Giovanni D’Andrea, Gennaro Bussone, Gianni Allais et al. · Neurological Sciences · 2009 · 70 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16